<!DOCTYPE html>
<html>
<head>
<meta http-equiv="X-UA-Compatible" content="IE=Edge" />
<meta charset="utf-8" />
</head>

<body style="margin: 0;">

<div id="p240" style="overflow: hidden; position: relative; background-color: white; width: 1210px; height: 935px;">
<style class="shared-css" type="text/css" >
.t {
	transform-origin: bottom left;
	z-index: 2;
	position: absolute;
	white-space: pre;
	overflow: visible;
	line-height: 1.5;
}
.text-container {
	white-space: pre;
}
@supports (-webkit-touch-callout: none) {
	.text-container {
		white-space: normal;
	}
}
</style>
<style type="text/css" >

#t1_240{left:35px;bottom:24px;letter-spacing:-0.34px;word-spacing:0.13px;}
#t2_240{left:306px;bottom:30px;}
#t3_240{left:313px;bottom:24px;letter-spacing:0.16px;}
#t4_240{left:346px;bottom:30px;}
#t5_240{left:351px;bottom:24px;letter-spacing:-0.16px;word-spacing:-0.22px;}
#t6_240{left:517px;bottom:30px;}
#t7_240{left:524px;bottom:24px;letter-spacing:-0.28px;word-spacing:-0.09px;}
#t8_240{left:288px;bottom:860px;letter-spacing:0.11px;word-spacing:-0.55px;}
#t9_240{left:288px;bottom:829px;letter-spacing:0.27px;word-spacing:-0.69px;}
#ta_240{left:1115px;bottom:27px;letter-spacing:0.23px;}
#tb_240{left:35px;bottom:777px;letter-spacing:0.02px;word-spacing:-1.07px;}
#tc_240{left:35px;bottom:757px;letter-spacing:-0.38px;}
#td_240{left:59px;bottom:757px;letter-spacing:0.16px;}
#te_240{left:428px;bottom:757px;}
#tf_240{left:35px;bottom:722px;letter-spacing:0.04px;word-spacing:0.14px;}
#tg_240{left:35px;bottom:702px;letter-spacing:0.03px;word-spacing:0.16px;}
#th_240{left:35px;bottom:683px;letter-spacing:0.09px;word-spacing:0.1px;}
#ti_240{left:35px;bottom:665px;letter-spacing:0.16px;word-spacing:0.03px;}
#tj_240{left:35px;bottom:645px;letter-spacing:-0.1px;word-spacing:0.28px;}
#tk_240{left:170px;bottom:645px;letter-spacing:0.16px;}
#tl_240{left:530px;bottom:645px;}
#tm_240{left:35px;bottom:608px;letter-spacing:0.05px;word-spacing:-0.81px;}
#tn_240{left:35px;bottom:589px;letter-spacing:0.02px;word-spacing:-0.38px;}
#to_240{left:35px;bottom:570px;letter-spacing:0.13px;word-spacing:0.06px;}
#tp_240{left:35px;bottom:551px;letter-spacing:0.13px;word-spacing:0.06px;}
#tq_240{left:35px;bottom:531px;letter-spacing:0.16px;}
#tr_240{left:396px;bottom:531px;}
#ts_240{left:35px;bottom:495px;letter-spacing:0.05px;word-spacing:-0.11px;}
#tt_240{left:35px;bottom:476px;letter-spacing:0.13px;word-spacing:0.05px;}
#tu_240{left:35px;bottom:457px;letter-spacing:0.02px;word-spacing:-0.93px;}
#tv_240{left:35px;bottom:437px;letter-spacing:0.19px;}
#tw_240{left:35px;bottom:418px;letter-spacing:-0.23px;word-spacing:1.63px;}
#tx_240{left:132px;bottom:418px;letter-spacing:0.16px;}
#ty_240{left:483px;bottom:418px;}
#tz_240{left:35px;bottom:382px;letter-spacing:0.13px;word-spacing:0.05px;}
#t10_240{left:35px;bottom:363px;letter-spacing:0.06px;word-spacing:0.12px;}
#t11_240{left:35px;bottom:343px;letter-spacing:0.05px;word-spacing:0.14px;}
#t12_240{left:35px;bottom:324px;letter-spacing:-0.23px;word-spacing:1.63px;}
#t13_240{left:132px;bottom:324px;letter-spacing:0.16px;}
#t14_240{left:493px;bottom:324px;}
#t15_240{left:35px;bottom:288px;letter-spacing:0.03px;word-spacing:0.15px;}
#t16_240{left:35px;bottom:269px;letter-spacing:0.15px;word-spacing:0.03px;}
#t17_240{left:35px;bottom:249px;letter-spacing:0.07px;word-spacing:0.12px;}
#t18_240{left:35px;bottom:229px;letter-spacing:-0.07px;word-spacing:0.25px;}
#t19_240{left:180px;bottom:229px;letter-spacing:0.16px;}
#t1a_240{left:540px;bottom:229px;}
#t1b_240{left:35px;bottom:194px;letter-spacing:-0.01px;word-spacing:0.19px;}
#t1c_240{left:35px;bottom:174px;letter-spacing:0.04px;word-spacing:0.14px;}
#t1d_240{left:35px;bottom:155px;letter-spacing:0.05px;word-spacing:-0.85px;}
#t1e_240{left:35px;bottom:135px;letter-spacing:0.08px;word-spacing:0.1px;}
#t1f_240{left:35px;bottom:116px;letter-spacing:0.16px;}
#t1g_240{left:386px;bottom:116px;}
#t1h_240{left:35px;bottom:80px;letter-spacing:0.07px;word-spacing:0.11px;}
#t1i_240{left:35px;bottom:61px;letter-spacing:0.03px;word-spacing:0.15px;}
#t1j_240{left:618px;bottom:777px;letter-spacing:0.04px;word-spacing:0.14px;}
#t1k_240{left:618px;bottom:759px;letter-spacing:0.14px;word-spacing:0.05px;}
#t1l_240{left:618px;bottom:739px;letter-spacing:0.16px;}
#t1m_240{left:979px;bottom:739px;}
#t1n_240{left:618px;bottom:702px;letter-spacing:0.06px;word-spacing:0.13px;}
#t1o_240{left:618px;bottom:683px;letter-spacing:0.03px;word-spacing:0.16px;}
#t1p_240{left:618px;bottom:665px;letter-spacing:0.11px;word-spacing:0.08px;}
#t1q_240{left:618px;bottom:645px;letter-spacing:0.16px;}
#t1r_240{left:979px;bottom:645px;}
#t1s_240{left:618px;bottom:608px;letter-spacing:0.04px;word-spacing:-0.37px;}
#t1t_240{left:618px;bottom:589px;letter-spacing:0.06px;word-spacing:0.12px;}
#t1u_240{left:618px;bottom:570px;letter-spacing:0.18px;word-spacing:0.01px;}
#t1v_240{left:618px;bottom:551px;letter-spacing:-0.23px;word-spacing:1.63px;}
#t1w_240{left:715px;bottom:551px;letter-spacing:0.16px;}
#t1x_240{left:1076px;bottom:551px;}
#t1y_240{left:618px;bottom:514px;letter-spacing:0.04px;word-spacing:0.15px;}
#t1z_240{left:618px;bottom:495px;letter-spacing:0.1px;word-spacing:0.08px;}
#t20_240{left:618px;bottom:476px;letter-spacing:0.03px;word-spacing:0.04px;}
#t21_240{left:618px;bottom:457px;letter-spacing:0.09px;word-spacing:0.1px;}
#t22_240{left:618px;bottom:437px;letter-spacing:0.16px;}
#t23_240{left:969px;bottom:437px;}
#t24_240{left:618px;bottom:401px;letter-spacing:0.1px;word-spacing:0.08px;}
#t25_240{left:618px;bottom:382px;letter-spacing:0.13px;word-spacing:0.06px;}
#t26_240{left:618px;bottom:363px;letter-spacing:0.15px;word-spacing:0.04px;}
#t27_240{left:618px;bottom:343px;letter-spacing:-0.07px;word-spacing:0.25px;}
#t28_240{left:763px;bottom:343px;letter-spacing:0.16px;}
#t29_240{left:1123px;bottom:343px;}
#t2a_240{left:618px;bottom:306px;letter-spacing:0.12px;word-spacing:-0.89px;}
#t2b_240{left:618px;bottom:288px;letter-spacing:0.04px;word-spacing:-0.75px;}
#t2c_240{left:618px;bottom:269px;letter-spacing:0.05px;word-spacing:0.14px;}
#t2d_240{left:618px;bottom:249px;letter-spacing:0.16px;}
#t2e_240{left:979px;bottom:249px;}
#t2f_240{left:618px;bottom:212px;letter-spacing:0.09px;word-spacing:0.1px;}
#t2g_240{left:618px;bottom:194px;letter-spacing:0.11px;word-spacing:0.08px;}
#t2h_240{left:618px;bottom:174px;letter-spacing:0.16px;}
#t2i_240{left:979px;bottom:174px;}
#t2j_240{left:618px;bottom:138px;letter-spacing:0.09px;word-spacing:0.09px;}
#t2k_240{left:618px;bottom:118px;letter-spacing:0.05px;word-spacing:0.14px;}
#t2l_240{left:618px;bottom:100px;letter-spacing:-0.04px;word-spacing:-0.55px;}
#t2m_240{left:618px;bottom:80px;letter-spacing:0.08px;word-spacing:0.11px;}
#t2n_240{left:618px;bottom:61px;letter-spacing:0.16px;}
#t2o_240{left:979px;bottom:61px;}
#t2p_240{left:23px;bottom:915px;letter-spacing:-0.14px;}

.s0_240{font-size:10px;font-family:ArialMT_5tg;color:#000;}
.s1_240{font-size:6px;font-family:ArialMT_5tg;color:#000;}
.s2_240{font-size:28px;font-family:Arial-BoldMT_5te;color:#000;}
.s3_240{font-size:17px;font-family:Arial-BoldMT_5te;color:#000;}
.s4_240{font-size:17px;font-family:ArialMT_5tg;color:#000;}
.s5_240{font-size:17px;font-family:ArialMT_5tg;color:#005B99;}
.s6_240{font-size:11px;font-family:Helvetica, Arial, sans-serif;color:#000;}
</style>
<style id="fonts240" type="text/css" >

@font-face {
	font-family: Arial-BoldMT_5te;
	src: url("fonts/Arial-BoldMT_5te.woff") format("woff");
}

@font-face {
	font-family: ArialMT_5tg;
	src: url("fonts/ArialMT_5tg.woff") format("woff");
}

</style>
<div id="pg240Overlay" style="width:100%; height:100%; position:absolute; z-index:1; background-color:rgba(0,0,0,0); -webkit-user-select: none;"></div>
<div id="pg240" style="-webkit-user-select: none;"><object width="1210" height="935" data="240/240.svg" type="image/svg+xml" id="pdf240" style="width:1210px; height:935px; z-index: 0;"></object></div>
<div class="text-container"><span id="t1_240" class="t s0_240">Version 4.2024 © 2024 National Comprehensive Cancer Network </span>
<span id="t2_240" class="t s1_240">© </span>
<span id="t3_240" class="t s0_240">(NCCN </span>
<span id="t4_240" class="t s1_240">© </span>
<span id="t5_240" class="t s0_240">), All rights reserved. NCCN Guidelines </span>
<span id="t6_240" class="t s1_240">® </span>
<span id="t7_240" class="t s0_240">and this illustration may not be reproduced in any form without the express written permission of NCCN. </span>
<span id="t8_240" class="t s2_240">NCCN Guidelines Version 4.2024 </span>
<span id="t9_240" class="t s2_240">Head and Neck Cancers </span>
<span id="ta_240" class="t s3_240">MS-99 </span>
<span id="tb_240" class="t s4_240">GEM20110714 phase III study. J Clin Oncol 2021;39:3273-3282. Available </span>
<span id="tc_240" class="t s4_240">at: </span><span id="td_240" class="t s5_240">https://www.ncbi.nlm.nih.gov/pubmed/34379443</span><span id="te_240" class="t s4_240">. </span>
<span id="tf_240" class="t s4_240">536. Samlowski WE, Moon J, Kuebler JP, et al. Evaluation of the </span>
<span id="tg_240" class="t s4_240">combination of docetaxel/carboplatin in patients with metastatic or </span>
<span id="th_240" class="t s4_240">recurrent squamous cell carcinoma of the head and neck (SCCHN): a </span>
<span id="ti_240" class="t s4_240">Southwest Oncology Group Phase II study. Cancer Invest 2007;25:182- </span>
<span id="tj_240" class="t s4_240">188. Available at: </span><span id="tk_240" class="t s5_240">http://www.ncbi.nlm.nih.gov/pubmed/17530488</span><span id="tl_240" class="t s4_240">. </span>
<span id="tm_240" class="t s4_240">537. Gibson MK, Li Y, Murphy B, et al. Randomized phase III evaluation of </span>
<span id="tn_240" class="t s4_240">cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head </span>
<span id="to_240" class="t s4_240">and neck cancer (E1395): an intergroup trial of the Eastern Cooperative </span>
<span id="tp_240" class="t s4_240">Oncology Group. J Clin Oncol 2005;23:3562-3567. Available at: </span>
<span id="tq_240" class="t s5_240">http://www.ncbi.nlm.nih.gov/pubmed/15908667</span><span id="tr_240" class="t s4_240">. </span>
<span id="ts_240" class="t s4_240">538. Forastiere AA, Metch B, Schuller DE, et al. Randomized comparison </span>
<span id="tt_240" class="t s4_240">of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus </span>
<span id="tu_240" class="t s4_240">methotrexate in advanced squamous-cell carcinoma of the head and neck: </span>
<span id="tv_240" class="t s4_240">a Southwest Oncology Group study. J Clin Oncol 1992;10:1245-1251. </span>
<span id="tw_240" class="t s4_240">Available at: </span><span id="tx_240" class="t s5_240">http://www.ncbi.nlm.nih.gov/pubmed/1634913</span><span id="ty_240" class="t s4_240">. </span>
<span id="tz_240" class="t s4_240">539. Chan ATC, Hsu M-M, Goh BC, et al. Multicenter, phase II study of </span>
<span id="t10_240" class="t s4_240">cetuximab in combination with carboplatin in patients with recurrent or </span>
<span id="t11_240" class="t s4_240">metastatic nasopharyngeal carcinoma. J Clin Oncol 2005;23:3568-3576. </span>
<span id="t12_240" class="t s4_240">Available at: </span><span id="t13_240" class="t s5_240">http://www.ncbi.nlm.nih.gov/pubmed/15809453</span><span id="t14_240" class="t s4_240">. </span>
<span id="t15_240" class="t s4_240">540. Jin Y, Cai XY, Shi YX, et al. Comparison of five cisplatin-based </span>
<span id="t16_240" class="t s4_240">regimens frequently used as the first-line protocols in metastatic </span>
<span id="t17_240" class="t s4_240">nasopharyngeal carcinoma. J Cancer Res Clin Oncol 2012;138:1717- </span>
<span id="t18_240" class="t s4_240">1725. Available at: </span><span id="t19_240" class="t s5_240">http://www.ncbi.nlm.nih.gov/pubmed/22684794</span><span id="t1a_240" class="t s4_240">. </span>
<span id="t1b_240" class="t s4_240">541. Jacobs C, Lyman G, Velez-Garcia E, et al. A phase III randomized </span>
<span id="t1c_240" class="t s4_240">study comparing cisplatin and fluorouracil as single agents and in </span>
<span id="t1d_240" class="t s4_240">combination for advanced squamous cell carcinoma of the head and neck. </span>
<span id="t1e_240" class="t s4_240">J Clin Oncol 1992;10:257-263. Available at: </span>
<span id="t1f_240" class="t s5_240">http://www.ncbi.nlm.nih.gov/pubmed/1732427</span><span id="t1g_240" class="t s4_240">. </span>
<span id="t1h_240" class="t s4_240">542. Burtness B, Goldwasser MA, Flood W, et al. Phase III randomized </span>
<span id="t1i_240" class="t s4_240">trial of cisplatin plus placebo compared with cisplatin plus cetuximab in </span>
<span id="t1j_240" class="t s4_240">metastatic/recurrent head and neck cancer: an Eastern Cooperative </span>
<span id="t1k_240" class="t s4_240">Oncology Group study. J Clin Oncol 2005;23:8646-8654. Available at: </span>
<span id="t1l_240" class="t s5_240">http://www.ncbi.nlm.nih.gov/pubmed/16314626</span><span id="t1m_240" class="t s4_240">. </span>
<span id="t1n_240" class="t s4_240">543. Grau JJ, Caballero M, Verger E, et al. Weekly paclitaxel for platin- </span>
<span id="t1o_240" class="t s4_240">resistant stage IV head and neck cancer patients. Acta Otolaryngol </span>
<span id="t1p_240" class="t s4_240">2009;129:1294-1299. Available at: </span>
<span id="t1q_240" class="t s5_240">http://www.ncbi.nlm.nih.gov/pubmed/19863327</span><span id="t1r_240" class="t s4_240">. </span>
<span id="t1s_240" class="t s4_240">544. Guardiola E, Peyrade F, Chaigneau L, et al. Results of a randomised </span>
<span id="t1t_240" class="t s4_240">phase II study comparing docetaxel with methotrexate in patients with </span>
<span id="t1u_240" class="t s4_240">recurrent head and neck cancer. Eur J Cancer 2004;40:2071-2076. </span>
<span id="t1v_240" class="t s4_240">Available at: </span><span id="t1w_240" class="t s5_240">http://www.ncbi.nlm.nih.gov/pubmed/15341981</span><span id="t1x_240" class="t s4_240">. </span>
<span id="t1y_240" class="t s4_240">545. Catimel G, Verweij J, Mattijssen V, et al. Docetaxel (Taxotere): an </span>
<span id="t1z_240" class="t s4_240">active drug for the treatment of patients with advanced squamous cell </span>
<span id="t20_240" class="t s4_240">carcinoma of the head and neck. EORTC Early Clinical Trials Group. Ann </span>
<span id="t21_240" class="t s4_240">Oncol 1994;5:533-537. Available at: </span>
<span id="t22_240" class="t s5_240">http://www.ncbi.nlm.nih.gov/pubmed/7918125</span><span id="t23_240" class="t s4_240">. </span>
<span id="t24_240" class="t s4_240">546. Stewart JS, Cohen EE, Licitra L, et al. Phase III study of gefitinib </span>
<span id="t25_240" class="t s4_240">compared with intravenous methotrexate for recurrent squamous cell </span>
<span id="t26_240" class="t s4_240">carcinoma of the head and neck [corrected]. J Clin Oncol 2009;27:1864- </span>
<span id="t27_240" class="t s4_240">1871. Available at: </span><span id="t28_240" class="t s5_240">http://www.ncbi.nlm.nih.gov/pubmed/19289630</span><span id="t29_240" class="t s4_240">. </span>
<span id="t2a_240" class="t s4_240">547. Fury MG, Pfister DG. Current recommendations for systemic therapy </span>
<span id="t2b_240" class="t s4_240">of recurrent and/or metastatic head and neck squamous cell cancer. J Natl </span>
<span id="t2c_240" class="t s4_240">Compr Canc Netw 2011;9:681-689. Available at: </span>
<span id="t2d_240" class="t s5_240">http://www.ncbi.nlm.nih.gov/pubmed/21636539</span><span id="t2e_240" class="t s4_240">. </span>
<span id="t2f_240" class="t s4_240">548. Price KA, Cohen EE. Current treatment options for metastatic head </span>
<span id="t2g_240" class="t s4_240">and neck cancer. Curr Treat Options Oncol 2012;13:35-46. Available at: </span>
<span id="t2h_240" class="t s5_240">http://www.ncbi.nlm.nih.gov/pubmed/22252884</span><span id="t2i_240" class="t s4_240">. </span>
<span id="t2j_240" class="t s4_240">549. Martinez-Trufero J, Isla D, Adansa JC, et al. Phase II study of </span>
<span id="t2k_240" class="t s4_240">capecitabine as palliative treatment for patients with recurrent and </span>
<span id="t2l_240" class="t s4_240">metastatic squamous head and neck cancer after previous platinum-based </span>
<span id="t2m_240" class="t s4_240">treatment. Br J Cancer 2010;102:1687-1691. Available at: </span>
<span id="t2n_240" class="t s5_240">http://www.ncbi.nlm.nih.gov/pubmed/20485287</span><span id="t2o_240" class="t s4_240">. </span>
<span id="t2p_240" class="t s6_240">Printed by Fredd Merc on 8/29/2024 4:45:54 AM. For personal use only. Not approved for distribution. Copyright © 2024 National Comprehensive Cancer Network, Inc., All Rights Reserved. </span></div>

</div>
</body>
</html>
